DA Davidson analyst Matt Summerville raised the firm’s price target on Cognex (CGNX) to $38 from $35 but keeps a Neutral rating on the shares after its Q3 earnings beat. The firm is implementing the previously disclosed, one-time commercial benefit into its model, while slightly reducing its 2026 EPS estimate, the analyst tells investors in a research note. Performance across Cognex segments appears to be seeing some level of stability and improvement, but the firm remains hesitant to assume that the company is poised for sustained upward inflection in consensus EPS views for time being amid ongoing end market cross currents, DA Davidson added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGNX:
- Cognex Earnings Call: Strong Growth Amid Challenges
- Cognex’s Growth Potential and Operational Efficiency Support Buy Rating
- Cognex price target raised to $45 from $43 at Baird
- Cognex’s Strategic Growth and Profitability Reinforce Buy Rating Amid Macroeconomic Concerns
- Cognex price target raised to $56 from $55 at Barclays